WO2014106800A8 - Substituted 2-amino pyrimidine derivatives as kinase inhibitors - Google Patents
Substituted 2-amino pyrimidine derivatives as kinase inhibitors Download PDFInfo
- Publication number
- WO2014106800A8 WO2014106800A8 PCT/IB2013/061358 IB2013061358W WO2014106800A8 WO 2014106800 A8 WO2014106800 A8 WO 2014106800A8 IB 2013061358 W IB2013061358 W IB 2013061358W WO 2014106800 A8 WO2014106800 A8 WO 2014106800A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrimidine derivatives
- present
- kinase
- inhibitor compounds
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention provides novel substituted 2-amino pyrimidine derivatives as kinase enzyme inhibitor compounds of formula (1), which may be therapeutically useful as kinase inhibitor, more particularly PI3K inhibitors. Formula (1) in which A, R1, R2 R3. R4, Q and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts and stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly PI3K enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN39/CHE/2013 | 2013-01-04 | ||
| IN39CH2013 | 2013-01-04 | ||
| IN3029/CHE/2013 | 2013-07-05 | ||
| IN3029CH2013 | 2013-07-05 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2014106800A2 WO2014106800A2 (en) | 2014-07-10 |
| WO2014106800A3 WO2014106800A3 (en) | 2014-12-18 |
| WO2014106800A8 true WO2014106800A8 (en) | 2015-02-19 |
Family
ID=51062519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2013/061358 Ceased WO2014106800A2 (en) | 2013-01-04 | 2013-12-27 | Substituted 2-amino pyrimidine derivatives as kinase inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014106800A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2920059A1 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
| MA40250A (en) | 2014-07-04 | 2017-05-10 | Lupin Ltd | Quinolizinone derivatives as pi3k inhibitors |
| CN106146411A (en) * | 2015-04-16 | 2016-11-23 | 上海医药工业研究院 | (S) preparation method of-2-(1-amino-propyl)-5-fluoro-3-phenyl-3H-quinazoline-4-one |
| CN104774183B (en) * | 2015-04-24 | 2017-10-13 | 合肥新诺华生物科技有限公司 | A kind of auspicious relax of formoxyl cuts down the preparation method of spit of fland calcium intermediate |
| US10385019B2 (en) * | 2015-06-30 | 2019-08-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and methods of use thereof |
| WO2017122116A1 (en) | 2016-01-15 | 2017-07-20 | Pfizer Inc. | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
| CN106588885B (en) * | 2016-11-10 | 2019-03-19 | 浙江大学 | 2- replaces aromatic ring-pyridine derivatives and preparation and application |
| JP6545747B2 (en) * | 2017-05-09 | 2019-07-17 | 山田化学工業株式会社 | Dye compound |
| CN107188856A (en) * | 2017-06-30 | 2017-09-22 | 宁夏医科大学 | The synthetic method of the methylpyrimidine of 2 amino, 4 hydroxyl 6 |
| JP7569688B2 (en) | 2017-12-22 | 2024-10-18 | ハイバーセル,インコーポレイテッド | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| TW202112767A (en) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CN115010640A (en) * | 2022-07-13 | 2022-09-06 | 苏州诚和医药化学有限公司 | Preparation process of brivaracetam |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2231641B1 (en) * | 2007-12-21 | 2016-06-01 | UCB Biopharma SPRL | Quinoxaline and quinoline derivatives as kinase inhibitors |
| WO2011101429A1 (en) * | 2010-02-22 | 2011-08-25 | F. Hoffmann-La Roche Ag | Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use |
-
2013
- 2013-12-27 WO PCT/IB2013/061358 patent/WO2014106800A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014106800A2 (en) | 2014-07-10 |
| WO2014106800A3 (en) | 2014-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014106800A8 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
| WO2014125408A3 (en) | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors | |
| PH12020500529A1 (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
| PH12016501338A1 (en) | Indazole compounds as irak4 inhibitors | |
| PH12016501355A1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| MX2013012776A (en) | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors. | |
| WO2014128669A3 (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
| PH12018501920B1 (en) | Bromodomain inhibitors | |
| HK1211942A1 (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| WO2014031438A3 (en) | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | |
| SA519410865B1 (en) | Coumarin-like Cyclic Compound as MEK Inhibitor and Use Thereof | |
| MX380928B (en) | KRAS G12C INHIBITORS. | |
| GEP20166484B (en) | Protein kinase inhibitors | |
| WO2014153100A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| WO2014153235A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| SA519401322B1 (en) | Heteroaryl carboxamide compounds as inhibitors of receptor-interacting serine/threonine protein kinase 2 | |
| MX2019010096A (en) | 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors. | |
| MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
| WO2016109217A3 (en) | Btk inhibitors | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| JOP20190233A1 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| EA201692557A1 (en) | CINOLYSINUM DERIVATIVES AS PI3K INHIBITORS | |
| WO2014072930A3 (en) | Fused pyridine derivatives as antibacterial agents | |
| MX2015012153A (en) | Pyrrolopyrimindine cdk9 kinase inhibitors. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct app. not ent. europ. phase |
Ref document number: 13870204 Country of ref document: EP Kind code of ref document: A2 |